IL-6 (-174 G/C) and IL-10 (-1082 G/A) polymorphisms and serum levels in Sudanese patients with end-stage renal disease and overt hepatitis B infection: a pilot comparative study Authors: Omer Boshra Mohamedsalih Shmed, Waleed Abdelateif Hussein Published: 2026 ABSTRACT AbstractBackgroundPatients with end-stage renal disease (ESRD) undergoing maintenance hemodialysis are at increased risk for persistent hepatitis B virus (HBV) infection. Host immunogenetic variations, particularly in cytokines regulating pro- and anti-inflammatory responses, may influence viral chronicity. This study evaluated the association of IL-6 − 174G/C and IL-10 − 1082G/A polymorphisms and their corresponding serum levels in Sudanese patients with overt HBV and ESRD-HBV.MethodsA case-control study was conducted among 68 HBV-infected individuals (31 ESRD-HBV and 37 overt HBV). Genotyping was performed using sequence-specific primer PCR (SSP-PCR), and serum cytokine concentrations were measured by ELISA. Statistical analyses were conducted using R software, applying non-parametric Wilcoxon rank-sum and Kruskal–Wallis tests.ResultsNo significant differences were observed between groups in IL-6 serum levels (p = 0.29) or genotype frequencies (p = 0.738), nor in IL-10 genotype distribution (p = 0.194). In contrast, IL-10 serum levels were significantly higher in the ESRD-HBV group compared to the overt HBV group (p = 0.00024). A significant genotype–phenotype association for IL-10 was identified within the ESRD-HBV cohort (p = 0.018), where carriers of the GA genotype exhibited higher serum IL-10 levels compared to AA and GG genotypes. This association was not observed in the overt HBV group (p = 0.33).ConclusionNo significant variation in IL-6 or IL-10 genotype frequencies was detected between the groups. Nevertheless, the IL-10 (− 1082G/A) polymorphism was related to differences in serum IL-10 concentrations among patients with concurrent HBV infection and ESRD. However, given the limited sample size and absence of key clinical confounders, these findings should be interpreted as exploratory and require validation in larger, well-characterized cohorts.Supplementary InformationThe online version contains supplementary material available at https://doi.org/10.1186/s12865-026-00854-4.Keywords: ESRD, Hepatitis B, IL-10, IL-6, Polymorphism, Sudan, Genotype–phenotype Introduction Hepatitis B virus (HBV) infection represents a critical global public health threat, contributing to approximately 1.1 million deaths annually due to complications such as cirrhosis and hepatocellular carcinoma (HCC) [1–4]. Sudan is classified as a region of high HBsAg endemicity, with seroprevalence rates reaching as high as 26% in certain areas [3, 5]. Within this landscape, patients with end-stage renal disease (ESRD) undergoing hemodialysis (HD) represent a highly vulnerable cohort [6]. The dialysis process, which involves blood recycling through plastic tubing and membranes, predisposes patients to blood-borne infections; studies in Sudanese renal units have reported HBsAg prevalence rates ranging from 7.6% to 45% [6–8]. The susceptibility of ESRD patients to persistent HBV infection is largely driven by a profound immune dysfunction termed uremic hypercytokinemia [9]. The accumulation of uremic toxins and exposure to bioincompatible dialysis membranes trigger a state of chronic systemic inflammation and premature immunosenescence [9, 10]. Central to this altered immune landscape are cytokines such as interleukin-6 (IL-6) and interleukin-10 (IL-10) [9]. IL-6 is a pleiotropic pro-inflammatory cytokine that modulates the hepatic response to systemic infection, while IL-10 acts as a potent anti-inflammatory and immunosuppressive agent [4, 11]. Critically, elevated IL-10 levels have been linked to the development of HBV chronicity by suppressing the adaptive immune responses necessary for viral clearance [1]. The regulation of these cytokines is heavily influenced by host genetic factors, specifically single nucleotide polymorphisms (SNPs) in their promoter regions [12]. Polymorphisms such as IL-10 − 1082 AG and IL-6 − 174 GC define high or low production phenotypes, which in turn affect disease susceptibility, progression to HCC, and patient survival [1, 11, 12]. Despite the high burden of both ESRD and HBV in Sudan, the specific immunogenetic interplay between these cytokine variants and HBV infection within the Sudanese population remains poorly understood [7, 13]. This study aimed to conduct an immunogenetic analysis of IL-6 and IL-10 in Sudanese ESRD patients with HBV infection. By utilizing a case-control design and a combination of sequence-specific primer PCR (SSP-PCR) for genotyping and ELISA for cytokine quantification, we sought to elucidate the association between these genetic markers and serum cytokine levels to better understand the pathophysiology of HBV in the uremic environment. Materials and methods Sample size and power analysis The sample size was relatively limited, primarily due to the restricted number of HBV-infected ESRD patients available in the study centers during the study period (N = 68). To evaluate the statistical reliability, a post-hoc power analysis was performed using G*Power software (version 3.1.9.7). For the primary comparison of serum IL-10 levels between the two groups, the study achieved a high statistical power (1-β) of 90% at a significance level (α) of 0.05. For the genotype–phenotype association within the ESRD-HBV subgroup (n = 31), the power was approximately 72%. While the study is sufficiently powered for major cytokine comparisons, the sample size was relatively limited due to the restricted number of HBV-infected ESRD patients available during the study period; as such, subgroup genetic findings should be interpreted as exploratory. Group definitions Overt HBV infection was defined as persistent positivity for hepatitis B surface antigen (HBsAg) for more than six months. This term is used to differentiate it from occult HBV infection (characterized by negative HBsAg and positive anti-HBc). This design allows for the exploration of cytokine profiles and genetic variations in the context of the uremic environment of ESRD versus standard chronic infection. Inclusion criteria Participants were adults (≥ 18 years), HBsAg positive for at least six months, and provided written informed consent. ESRD-HBV patients were required to be on maintenance hemodialysis. Exclusion criteria Participants were excluded if they had co-infections (HCV, HIV), autoimmune diseases, chronic inflammatory disorders, malignancy, or were receiving immunosuppressive therapy. Clinical and methodological considerations Due to limitations in clinical data availability, detailed virological parameters (HBV DNA, HBeAg, fibrosis staging) were not consistently available. Additionally, factors related to hemodialysis (duration, membrane type) were not fully controlled. The ‘Overt HBV’ group was defined by HBsAg positivity for 6 months without clinical evidence of renal failure. Due to resource-limited settings, consistent data for HBV DNA viral loads and liver fibrosis staging (FibroScan or biopsy) were unavailable for all participants, which is a recognized limitation in the clinical stratification of this cohort. DNA extraction Peripheral blood samples were collected in EDTA-containing tubes for genetic analysis. Genomic DNA was extracted from 300 µL of whole blood using the G-spin™ Total DNA Extraction Mini Kit (Intron Biotechnology, South Korea), following the manufacturer’s instructions. The quality and integrity of the extracted DNA were assessed by electrophoresis on a 1.5% agarose gel using 5-in-1 loading dye [14]. All DNA samples were stored at − 20 °C until further PCR analysis. Cytokine genotyping (SSP-PCR) Genotyping of the IL-6 (− 174G/C) and IL-10 (− 1082G/A) polymorphisms was performed using the sequence-specific primer polymerase chain reaction (SSP-PCR) technique. PCR reactions were prepared in a final volume of 20 µL using 5× FIREPOL® Master Mix (Solis BioDyne, Estonia). For IL-10 (− 1082G/A) genotyping, a common reverse primer (5′-CAG CCG TTC CAT TTT ACT TTC-3′) was used in combination with either the G-specific forward primer (5′-TAC TAA GGC TTC TTT GGG AG-3′) or the A-specific forward primer (5′-CTA CTA AGG CTT CTT TGG GAA-3′), generating a 550 bp amplicon [14]. In the IL-6 (− 174G/C) genotyping, each reaction contained a generic antisense primer (5′-GCC TCA GAG ACA TCA CCA GTC C-3′) and one of two allele-specific sense primers: the C-allele primer (5′-CCC CTA GTT GTG TCT TGC C-3′) or the G-allele primer (5′-CCC CTA GTT GTG TCT TGC G-3′), yielding a 240 bp PCR product [15]. PCR amplification was performed using a Techne Thermal Cycler (UK). Thermal cycling conditions for IL-10 consisted of an initial denaturation at 95 °C for 1 min, followed by 35 cycles of denaturation at 95 °C for 30 s, annealing at 58 °C for 30 s, and extension at 72 °C for 30 s [14]. For IL-6, amplification involved 35 cycles with denaturation at 95 °C for 30 s, annealing at 55.5 °C for 30 s, and extension at 72 °C for 30 s [15]. A final extension step at 72 °C for 5 min was applied for both reactions [14, 15]. PCR products were separated by electrophoresis on a 2% agarose gel stained with ethidium bromide in 1× TBE buffer at 100 V for 30 min. 100 bp DNA ladder was used as a molecular size marker for 240 bp PCR Product and 50 bp marker for 550 bp PCR product. Both ladders were calibrated against the same internal standards to ensure consistency in size determination. To ensure genotyping accuracy, 10% of the samples were randomly selected for duplicate analysis. While specific internal control primers (e.g., human β-globin) were not multiplexed in every reaction, the presence of clear bands in the majority of lanes and consistent results in replicates confirmed the reliability of the SSP-PCR assay. Successful amplification of the target gene regions was confirmed by 2% agarose gel electrophoresis. For the IL-6 (− 174G/C) polymorphism, a distinct 240 bp band indicated successful genotyping (Fig. 1), whereas the IL-10 (− 1082G/A) polymorphism yielded a specific 550 bp amplification product (Fig. 2). A representative agarose (2%) gel electrophoresis of SSP-PCR product (240 bp) for genotyping of Interleukin-6 (-174 C/G); M: 100 bp DNA marker. Lanes 2, 3 and 4, 5: represent heterozygous individuals (CG). Lanes 6, 7: represent homozygous wild (CC) individual. Lanes 8, 9: represent homozygous mutant (GG) individual. Full-length unedited gel images are provided in Supplementary File 1 A representative agarose (2%) gel electrophoresis of SSP-PCR product (550 bp) for genotyping of Interleukin-10 (-1082 G/A); M: 50 bp DNA marker. Lanes 2, 3; 6, 7 and 8, 9: represent heterozygous individuals (GA). Lanes 4, 5: represent Homozygous wild (GG) individual; lane 4 represents the absence of the A allele, while lane 5 confirms the presence of the G allele. Full-length, unedited gel images are provided in Supplementary File 1 Serum cytokine quantification (ELISA) Serum samples were obtained from blood collected in plain (clot activator) tubes and stored at − 20 °C. For the ESRD group, samples were collected pre-hemodialysis to avoid procedural influence on cytokine concentrations. Serum levels of IL-6 and IL-10 were measured using commercial ELISA MAX™ Standard Sets (BioLegend, USA; #430501 for IL-6 and #430601 for IL-10) were used to measure serum cytokine levels. The assay standard ranges were 7.8–500 pg/mL for IL-6 and 3.9–500 pg/mL for IL-10, with intra- and inter-assay variation typically maintained below 10% according to manufacturer protocols. All samples were analyzed in duplicate to ensure analytical reproducibility, and optical density was measured at 450 nm using a microplate reader. Statistical analysis Statistical analyses were performed using R software version 4.4.0 [16]. Descriptive statistics were used to summarize genotype and allele frequencies. Differences in genotype and allele distributions between groups were assessed using the chi-square (χ²) test or Fisher’s exact test, as appropriate. Deviation from Hardy–Weinberg Equilibrium (HWE) was evaluated using the chi-square test to assess the representativeness of the study population. The normality of continuous variables (cytokine levels) was assessed using the Shapiro–Wilk test. As the data significantly deviated from a normal distribution (p < 0.05), non-parametric tests were applied. The Mann–Whitney U test was used for pairwise comparisons of cytokine levels between the ESRD-HBV and overt HBV groups. For comparisons involving more than two genotype groups, the Kruskal–Wallis test was employed. Given the exploratory nature of the cytokine association analysis and the limited number of independent loci (IL-6 and IL-10), no formal correction for multiple comparisons (e.g., Bonferroni adjustment) was applied. However, exact p-values are reported to ensure transparent interpretation. A p-value < 0.05 was considered statistically significant. Results Genotyping and frequency distribution The genotype and allele frequencies of the IL-6 (− 174G/C) and IL-10 (− 1082G/A) polymorphisms were analyzed in patients with end-stage renal disease and HBV (ESRD-HBV, n = 31) and those with chronic overt HBV (n = 37). As shown in Table 1, no statistically significant differences were observed in either genotype or allele distributions between the two groups (p 0.05). Table 1Genotype Distributions, Allele Frequencies, and Hardy-Weinberg Equilibrium (HWE) AnalysisGenetic MarkerESRD-HBV (n = 31)Overt HBV (n = 37)p-value*IL−6 (−174 G/C)0.738 GG12 (38.7%)17 (45.9%) GC14 (45.2%)14 (37.8%) CC5 (16.1%)6 (16.2%) G allele frequency0.610.650.761 C allele frequency0.390.35 HWE (p-value)0.7910.301—IL−10 (−1082 G/A)0.194 GG19 (61.3%)21 (56.8%) GA8 (25.8%)14 (37.8%) AA4 (12.9%)2 (5.4%) G allele frequency0.740.760.887 A allele frequency0.260.24 HWE (p-value)0.0680.865—* p-values were calculated using Chi-square or Fisher’s exact test for genotype distributions and allele comparisons Genotype Distributions, Allele Frequencies, and Hardy-Weinberg Equilibrium (HWE) Analysis * p-values were calculated using Chi-square or Fisher’s exact test for genotype distributions and allele comparisons Interleukin-6 (− 174G/C) For the IL-6 − 174G/C polymorphism, the GC genotype was the most frequent in the ESRD-HBV group (45.2%), while the GG genotype was most common in the Overt HBV group (45.9%) (Table 1). The CC genotype was observed at similar frequencies in both groups (16.1% vs. 16.2%, respectively). The G allele was predominant in both cohorts (0.61 in ESRD-HBV and 0.65 in overt HBV), with no significant association with disease status (p = 0.761, Table 1). Interleukin-10 (− 1082G/A) Regarding the IL-10 − 1082G/A polymorphism, the GG genotype was the most prevalent in both ESRD-HBV and overt HBV groups (61.3% and 56.8%, respectively), followed by the GA genotype, which was more frequent in the overt HBV group (37.8%) compared to the ESRD-HBV group (25.8%). The AA genotype was less frequent in both groups. The G allele remained dominant in both ESRD-HBV and overt HBV patients (0.74 and 0.76, respectively), with no significant difference observed between groups (Table 1). Hardy–Weinberg equilibrium Hardy–Weinberg equilibrium analysis demonstrated that all loci were in equilibrium in both study groups (p 0.05), except for a borderline deviation observed for the IL-10 locus in the ESRD-HBV group (p = 0.068), while all other comparisons remained within expected distributions (Table 1). Genotype frequency distributions showed no statistically significant differences between ESRD-HBV patients and Overt HBV patients for either IL-6 (p = 0.738) or IL-10 (p = 0.194)(Table 1). Quantitative comparison of serum cytokine levels Serum cytokine concentrations were compared between the two study groups using the Wilcoxon rank-sum test. No statistically significant difference was observed in serum IL-6 levels between the ESRD-HBV group and the Overt HBV group (p = 0.29) as illustrated in Fig. 3. Boxplot of serum IL-6 concentrations (pg/mL) in ESRD-HBV and Overt HBV patients. The box represents the middle 50% of values, the horizontal line indicates the median, whiskers show the spread of most values, and individual dots represent measured serum IL-6 levels. No significant difference was observed between groups (Wilcoxon test, p = 0.29). Full-length, unedited gel images are provided in Supplementary File 1 In contrast, serum IL-10 concentrations were significantly higher in the ESRD-HBV cohort compared to the Overt HBV control group (p = 0.00024) as shown in Fig. 4. Boxplot of serum IL-10 concentrations (pg/mL) in ESRD-HBV and Overt HBV patients. The box represents the middle 50% of values, the horizontal line indicates the median, whiskers show the spread of most values, and individual dots represent measured serum IL-10 levels. Significant difference was observed between groups (Wilcoxon test, p = 0.00024). Full-length, unedited gel images are provided in Supplementary File 1 Genotype–phenotype associations The relationship between cytokine gene polymorphisms and serum cytokine concentrations was evaluated using the Kruskal–Wallis test. For the IL-6 (− 174G/C) polymorphism, no significant association was observed between genotype and serum IL-6 levels in either the ESRD-HBV group (p = 0.45) or the Overt HBV group (p = 0.71) as observed in Fig. 5. Impact of IL-6 genotype on serum levels. Faceted boxplots show no significant genotype–phenotype association in the ESRD-HBV group (p = 0.45) or the overt HBV group (p = 0.71). Boxes represent the interquartile range, with the median indicated by the horizontal line, and individual dots represent measured serum IL-6 concentrations for each genotype (CC, GC, and GG) For the IL-10 (− 1082G/A) polymorphism presented in Fig. 6, no significant association was detected in the Overt HBV group (p = 0.33). However, a statistically significant genotype–phenotype association was identified in the ESRD-HBV group (p = 0.018). Notably, ESRD-HBV patients carrying the GA genotype exhibited higher serum IL-10 concentrations compared with those harboring the AA or GG genotypes. Impact of IL-10 genotype on serum levels. Faceted boxplots show a significant genotype–phenotype association in the ESRD-HBV group (p = 0.018), but not in the overt HBV group (p = 0.33). Boxes represent the interquartile range, with the median indicated by the horizontal line, and individual dots represent measured serum IL-10 concentrations for each genotype (AA, GA, and GG) A comprehensive overview of the comparative serum levels and the genotype–phenotype associations for both cytokines across the study groups is summarized in Table 2. Table 2Summary of key statistical findingsParameterGroupStatistical TestResult Summaryp-valueSerum IL−6 levelsESRD-HBV vs. Overt HBVWilcoxon rank-sumNo significant difference0.29Serum IL−10 levelsESRD-HBV vs. Overt HBVWilcoxon rank-sumSignificantly higher in ESRD-HBV0.00024IL−6 Genotype–PhenotypeESRD-HBVKruskal–WallisNo significant association0.45IL−6 Genotype–PhenotypeOvert HBVKruskal–WallisNo significant association0.71IL−10 Genotype–PhenotypeESRD-HBVKruskal–WallisSignificant association0.018IL−10 Genotype–PhenotypeOvert HBVKruskal–WallisNo significant association0.33Kruskal–Wallis test was used for genotype–phenotype associations within groupsWilcoxon rank-sum test was used for comparisons between groups Summary of key statistical findings Kruskal–Wallis test was used for genotype–phenotype associations within groups Wilcoxon rank-sum test was used for comparisons between groups Discussion The clinical outcome of hepatitis B virus (HBV) infection is determined by complex interactions between viral factors and host immune responses, particularly cytokine-mediated pathways [13, 17]. In this context, the balance between pro-inflammatory and anti-inflammatory cytokines is critical for disease progression [17]. In the present study, IL-6 serum levels (p = 0.29) and genotype distributions (p = 0.738) were not significantly different between the ESRD-HBV and overt HBV groups. This indicates comparable IL-6–mediated inflammatory activity in both populations, suggesting limited involvement of IL-6 variation in distinguishing these clinical conditions [18]. This finding aligns with previous studies reporting weak or inconsistent associations between IL-6 polymorphisms and HBV persistence [19–23]. In contrast, IL-10 levels were significantly higher in the ESRD-HBV group (p = 0.00024), indicating a more immunosuppressive cytokine profile. This suggests enhanced anti-inflammatory signaling that may favor viral persistence through the suppression of antiviral immune responses [1, 17, 24, 25]. Furthermore, a significant genotype–phenotype association was observed only in the ESRD-HBV group (p = 0.018), where GA genotype carriers exhibited higher IL-10 levels [26]. The IL-10–1082 A/G polymorphism is known to influence transcriptional activity, with the GA genotype typically associated with intermediate-to-high cytokine production [2, 26, 27]. The absence of this association in the overt HBV group (p = 0.33) suggests that the functional impact of IL-10 genetic variation is context-dependent. In ESRD patients, immune dysregulation and chronic inflammatory stress may amplify the phenotypic expression of IL-10 polymorphisms, revealing a gene-environment interaction that is not evident in non-ESRD HBV infection [1, 26, 28–30]. Study limitations Several limitations of this study should be acknowledged: Sample Size and Statistical Power:The study population (N = 68), particularly the ESRD-HBV subgroup, was relatively small, which limits the ability to detect modest genetic effects and increases the risk of type II error. Although post-hoc analysis indicated adequate power for primary cytokine comparisons, subgroup genetic associations remain exploratory and may be susceptible to overfitting. Therefore, these findings should be interpreted with caution and require validation in larger cohorts. Sample Size and Statistical Power: The study population (N = 68), particularly the ESRD-HBV subgroup, was relatively small, which limits the ability to detect modest genetic effects and increases the risk of type II error. Although post-hoc analysis indicated adequate power for primary cytokine comparisons, subgroup genetic associations remain exploratory and may be susceptible to overfitting. Therefore, these findings should be interpreted with caution and require validation in larger cohorts. Absence of a Healthy Control Group:The lack of a healthy, non-HBV, non-ESRD control group limits the ability to determine whether the observed cytokine alterations—particularly the elevated IL-10 levels in ESRD-HBV patients—represent disease-specific immunological changes or reflect baseline differences between chronic disease states. Inclusion of a healthy control population would provide essential baseline reference values. Absence of a Healthy Control Group: The lack of a healthy, non-HBV, non-ESRD control group limits the ability to determine whether the observed cytokine alterations—particularly the elevated IL-10 levels in ESRD-HBV patients—represent disease-specific immunological changes or reflect baseline differences between chronic disease states. Inclusion of a healthy control population would provide essential baseline reference values. Unmeasured Clinical and Virological Confounders:A major limitation is the absence of key clinical and virological variables known to influence cytokine expression and HBV persistence. These include HBV DNA viral load, HBeAg status, liver enzyme levels (ALT/AST), duration of hemodialysis, residual renal function, dialyzer membrane type, and the use of antiviral or immunosuppressive therapies. The lack of these parameters precluded adjusted analyses and limits causal inference, restricting interpretation to associative findings. Unmeasured Clinical and Virological Confounders: A major limitation is the absence of key clinical and virological variables known to influence cytokine expression and HBV persistence. These include HBV DNA viral load, HBeAg status, liver enzyme levels (ALT/AST), duration of hemodialysis, residual renal function, dialyzer membrane type, and the use of antiviral or immunosuppressive therapies. The lack of these parameters precluded adjusted analyses and limits causal inference, restricting interpretation to associative findings. Limited Clinical Characterization:Detailed clinical staging and fibrosis assessment for the Overt HBV group were not available. This limits the ability to stratify disease severity and may obscure relationships between cytokine levels and disease progression. Limited Clinical Characterization: Detailed clinical staging and fibrosis assessment for the Overt HBV group were not available. This limits the ability to stratify disease severity and may obscure relationships between cytokine levels and disease progression. Genetic Heterogeneity:The Sudanese population is genetically diverse; however, stratification by ethnic or regional subgroups was not performed. This may affect the generalizability of allele frequencies and genotype–phenotype associations. Genetic Heterogeneity: The Sudanese population is genetically diverse; however, stratification by ethnic or regional subgroups was not performed. This may affect the generalizability of allele frequencies and genotype–phenotype associations. Lack of Functional Validation:The functional impact of the investigated promoter polymorphisms on gene expression was not directly assessed. Measurements such as mRNA expression levels or promoter activity assays would be necessary to confirm the biological relevance of the observed associations. Lack of Functional Validation: The functional impact of the investigated promoter polymorphisms on gene expression was not directly assessed. Measurements such as mRNA expression levels or promoter activity assays would be necessary to confirm the biological relevance of the observed associations. Cross-Sectional Study Design:As a cross-sectional study, the findings reflect associations at a single time point and cannot establish temporal or causal relationships between cytokine gene polymorphisms and HBV persistence. Cross-Sectional Study Design: As a cross-sectional study, the findings reflect associations at a single time point and cannot establish temporal or causal relationships between cytokine gene polymorphisms and HBV persistence. Future perspectives Considering these limitations, this study serves as a preliminary basis for the following hypotheses: Validation in Larger Cohorts:The association between the IL-10 − 1082G/A polymorphism and serum cytokine levels should be validated in larger, multi-center cohorts to confirm reproducibility and improve statistical robustness. Validation in Larger Cohorts: The association between the IL-10 − 1082G/A polymorphism and serum cytokine levels should be validated in larger, multi-center cohorts to confirm reproducibility and improve statistical robustness. Integration of Clinical and Virological DataFuture studies incorporating HBV DNA levels, HBeAg status, liver function markers, and detailed dialysis-related parameters will allow for multivariate modeling and more accurate interpretation of cytokine regulation. Integration of Clinical and Virological Data Future studies incorporating HBV DNA levels, HBeAg status, liver function markers, and detailed dialysis-related parameters will allow for multivariate modeling and more accurate interpretation of cytokine regulation. Functional CharacterizationExperimental studies, including mRNA expression analysis and promoter activity assays, are needed to elucidate the mechanistic role of IL-10 polymorphisms in modulating immune responses under uremic conditions. Functional Characterization Experimental studies, including mRNA expression analysis and promoter activity assays, are needed to elucidate the mechanistic role of IL-10 polymorphisms in modulating immune responses under uremic conditions. Longitudinal Study DesignsProspective longitudinal studies tracking cytokine dynamics over time would provide insight into their role in HBV persistence and disease progression. Longitudinal Study Designs Prospective longitudinal studies tracking cytokine dynamics over time would provide insight into their role in HBV persistence and disease progression. Gene–Environment InteractionsInvestigating the interaction between host genetic background and environmental factors such as hemodialysis exposure may clarify why genotype–phenotype associations are more pronounced in ESRD-HBV patients. Gene–Environment Interactions Investigating the interaction between host genetic background and environmental factors such as hemodialysis exposure may clarify why genotype–phenotype associations are more pronounced in ESRD-HBV patients. Population-Based Genetic StudiesBroader studies across diverse Sudanese and African populations are warranted to assess ethnic variability and enhance the generalizability of immunogenetic findings Population-Based Genetic Studies Broader studies across diverse Sudanese and African populations are warranted to assess ethnic variability and enhance the generalizability of immunogenetic findings Conclusion In conclusion, this preliminary study found no significant differences in the distribution of IL-6 or IL-10 genotypes between the study groups. However, an association between IL-10 (− 1082G/A) genotype and serum IL-10 levels was observed within patients with concurrent overt HBV infection and ESRD, suggesting that genetic variation may be linked to cytokine levels in this specific clinical setting. However, given the modest sample size and the absence of healthy controls and additional clinical variables, the results should be interpreted cautiously. Larger, well-designed multicenter studies are needed to confirm these observations and to clarify whether such polymorphisms have clinical relevance for disease progression, prognosis, or personalized management. Supplementary Information Supplementary Material 1. Acknowledgements The authors express their sincere gratitude to the staff of the Al-Neelain University laboratories and the participating dialysis centers in Khartoum State for their technical assistance. We also extend our deepest thanks to the patients who participated in this study for their cooperation and contribution to medical research. The authors note that a preliminary version of this study was posted as a preprint under the name Omer B. Mohamedsalih (medRxiv, https://doi.org/10.1101/2023.01.17.23284661). In this final submission, the author’s name has been corrected to Omer B. Mohamed Saleh. Furthermore, the title and study objectives have been revised, and the statistical methodology updated. These refined analyses and results supersede those presented in the original preprint. Authors’ contributions OS conceived and designed the study, performed the laboratory work and statistical analysis, and drafted the manuscript. WH supervised the study, contributed to the study design, sample collection, data interpretation, and critically revised the manuscript. All authors read and approved the final manuscript. Funding This work did not receive any specific grant from funding agencies in the public, commercial, or not for profit sectors. Data availability The raw data supporting the conclusions of this study, including genotype frequencies and serum measurements, are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Ethical Committee of the Scientific Research Deanship, Alneelain University. All procedures were conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants prior to sample collection. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The raw data supporting the conclusions of this study, including genotype frequencies and serum measurements, are available from the corresponding author upon reasonable request.